Monte Rosa Therapeutics elects three Class I directors, ratifies auditor at 2025 annual meeting

Monte Rosa Therapeutics, Inc.

Elected Christine Siu, Kimberly Blackwell, and Jan Skvarka as Class I directors for three-year terms ending in 2028.
Christine Siu received 52.1M for, 3.4M withheld; Jan Skvarka received 44.8M for, 10.7M withheld.
Ratified Deloitte & Touche LLP as independent auditor for FY 2025 with 57.9M for, 139k against, 12.9k abstain.
Record date April 16, 2025; 61,509,821 shares outstanding.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.